Breast Cancer Clinical Trials 2023

What Are Breast Cancer Clinical Trials?

Breast cancer is a cancer that forms in the cells of breasts. Breast cancer symptoms can vary from swollen lymph nodes to a new lump in the breast or armpit. Breast cancer may spread into the surronding tissues if the disease progresses.

In clinical trials, men and women with all types and stages of breast cancer participate in helping doctors and scientists find better treatment methods and medication. In addition, many researchers are looking at innovative therapeutics to determine if they are safe, effective, or even better than standard treatments.

Why Is Breast Cancer Being Studied Through Clinical Trials?

Recent statistics from 2020 have shown a significant increase in women's breast cancer. In addition, breast cancer is now the most diagnosed type of cancer, with 1 in every 3 women diagnosed.

Clinical studies focus on trying out new drugs (medication), different treatment plans, advanced surgery and radiation methods, and various other types of therapy.

What Are The Types of Treatments Available For Breast Cancer?

A breast cancer diagnosis is confirmed by taking a biopsy of the concerned tissue. How breast cancer is treated varies on its type and stage. These treatments include surgery, chemotherapym hormone therapy, targeted drugs, and immunotherapy, and a combination of these are used to treat breast cancer patients.

What Are Some Recent Breakthrough Clinical Trials For Breast Cancer?

There has been several landmark studies involving breast cancer in recent years. Some of the most notable studies are:

2023: Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer The Institute of Cancerology Strasbourg, Strasbourg, France, found that combining chemotherapy with the immunotherapy medicine pembrolizumab (Keytruda) can extend the lives of certain patients with advanced triple-negative breast cancer. This is significant because, in general, triple-negative breast cancer is more aggressive, harder to cure, and recurring than other forms of the disease.

2023: Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer The Memorial Sloan Kettering Cancer Center found that trastuzumab deruxtecan (Enhertu), used for the treatment of HER2-low breast cancers, can prolong the life of the patients by up to 6 months. This is significant because the FDA approved this drug for people who had previously received chemotherapy or had their cancer returned within 6 months of surgery or completion of chemotherapy.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Breast Cancer

Dr. Shanu Modi, M.D

Shanu Modi, M.D is a medical oncologist at Memorial Sloan Kettering Cancer Center. Her research focuses on the clinical development of new breast cancer treatments, emphasizing evaluating targeted biological anticancer drugs.